Supporting Sexual Recovery in Women With Bladder Cancer
NCT ID: NCT07091565
Last Updated: 2025-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
60 participants
OBSERVATIONAL
2025-08-01
2029-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study has three main parts. First, it reviews what is already known. Next, it involves talking to women with bladder cancer and the doctors and nurses who care for them. Finally, the team will use what they learn to create a toolkit to help healthcare workers support women's sexual recovery.
Women with bladder cancer are helping to design this study. Their input shapes the questions and tools. The final toolkit will include training for doctors and nurses and be shared online and through charities. The aim is to make this part of regular healthcare.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sexual Quality of Patients After Bladder Cancer Cystectomy
NCT04964895
Recovery Support for Bladder Cancer Patients and Caregivers
NCT04055311
Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study
NCT07339761
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
NCT06350734
Bladder Cancer Patient-Reported Outcomes
NCT01090388
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There are different types of bladder cancer, and each requires a different treatment. In high-risk types, a more intensive treatment is required. The patient may need to have their bladder removed. The bladder is replaced with an alternative option for urine drainage such as a bag on the skin. In bladder removal, evidence tells us that there will be an impact on a woman's sexual well-being.
Sexual recovery is an important aspect of personal wellbeing and quality of life after cancer treatment. We have worked with women to develop this proposal and they tell us this is important to them.
This study aims to examine this aspect of well-being in women with bladder cancer and having bladder removal. The study will develop a toolkit alongside women to support sexual recovery in this group of patients.
What will the study involve? The study has been designed in stages to breakdown the individual elements.
Stage 1:
The initial stage involves a detailed examination of the existing literature to understand what needs to be discovered.
Stage 2:
The next stage requires in-depth investigation through interviewing patients individually or in a group. Doctors and nurses will also be interviewed about sexual well-being and bladder cancer. Findings from these interviews will be looked at to identify common themes and to understand how care is given.
Stage 3:
Findings from Stages 1 and 2 will be used to co-design a toolkit. The toolkit will be designed in partnership with patients and clinical experts.
It is anticipated that the toolkit will involve education sessions face to face or online to allow the healthcare provider to give better care. The toolkit will be tested to check it is meeting the needs of patients and that it is acceptable to users.
Public Involvement and Engagement This is a co-design project. This means that patients are involved in the project at every stage. At the start, a project codesign group has been created. This includes five patients with experience of bladder cancer. The group is from different backgrounds and further efforts will be made to include people from under-represented groups. For example, the patient group thought it was important for patients to be offered interviews alone or in groups. This was particularly important for the members from under-represented groups, so the study design was amended.
Considerations Prior to starting, ethical approval will be sought to be sure the study will not cause harm. Patients will be invited to participate by post or email. Participation will be voluntary and can be withdrawn. Recruited patients will be allocated an anonymous identification code and all data will be stored in a safe way. Some participants may feel upset during the study and need extra support. If this happens, they will be referred for specialist help.
Outcomes A toolkit will be designed for healthcare professionals. The toolkit will help healthcare professionals to support women's sexual recovery. The toolkit will be tested to make sure it works. The findings will be shared with patients online and through charity groups. This will be achieved through explanatory animations. Doctors and nurses will be encouraged to complete the training and will be alerted to it at professional meetings and groups. The final aim is to include this toolkit within clinical training and guidelines.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient
Experienced patients
Qualitative interview/Focus group
Participants will take part in a 1:1 interview or focus group
HCP
Experienced healthcare professionals
Qualitative interview/Focus group
Participants will take part in a 1:1 interview or focus group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Qualitative interview/Focus group
Participants will take part in a 1:1 interview or focus group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a diagnosis of BCa-any grade/stage and have had a cystectomy (bladder removal)
* At least 6 months after cystectomy
* \>/ 18 years old
* Written informed consent.
HCP Inclusion
* All those working directly within a bladder cancer speciality
* Professional registration
* Written informed consent
Patient Exclusion
* Poor command of the English language to the extent that the researcher judges this to critically undermine the ability to achieve the objectives of the interview.
* A judgement by the researcher or the individual's clinician, based on either clinical appraisal (capacity assessment) or review of the individual's medical notes, that the individual has a cognitive functioning impairment that would interfere with ability to understand and complete the interview.
* Documentation in the accessible medical notes of a psychiatric condition that would hamper participation in interview.
* A judgement by the researcher or the individual's clinician, based on either clinical appraisal or review of the individual's medical notes, that the individual is too ill to participate; or is ill enough that participation would produce an unreasonable burden on that individual.
* Aged \<18 years.
HCP Exclusion:
-Those without professional registration
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guy's & St Thomas' NHS FT
UNKNOWN
The Royal Marsden NHS FT
UNKNOWN
Sheffield Teaching Hospitals NHS FT
UNKNOWN
King's College London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King's College, London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
335939
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.